Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/8/2017
SIETES contiene 91969 citas

 
 
 1 a 20 de 509 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]
2. Cita con resumen
Gedeborg R, Svennblad B, Holm L, Sjögren H, Bardage C, Personne M, Sjöberg G, Feltelius N, Zethelius B. Increased availability of paracetamol in Sweden and incidence of paracetamol poisoning: using laboratory data to increase validity of a population-based registry study. Pharmacoepidemiol Drug Saf 2017;26:518-27. [Ref.ID 101958]
3. Cita con resumen
Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]
4. Cita con resumen
Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]
5. Cita con resumen
Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]
6. Cita con resumen
Anónimo. FDA approves Differin Gel 0.1% for over-the-counter use to treat acne. FDA U.S. Food and Drug Administration 2016:8 de julio. [Ref.ID 100485]
8.Tiene citas relacionadas Cita con resumen
Anónimo. Zecuity (sumatriptan) migraine patch: Drug Safety Communication - FDA evaluating risk of burns and scars. FDA U.S. Food and Drug Administration 2016:2 de junio. [Ref.ID 100357]
9. Cita con resumen
Imbernón-Moya A, Chico R, Aguilar-Martínez A. Manifestaciones cutáneas y mucosas asociadas al consumo de cocaína. Med Clin (Barc) 2016;146:544-9. [Ref.ID 100354]
11.Tiene citas relacionadas Cita con resumen
Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K, Soong W, Worm M, Szepietowski JC, Sofen H, Kawashima M, Wu R, Weinstein SP, Graham NMH, Pirozzi G, Teper A, Sutherland ER, Mastey V, Stahl N, Yancopoulos GD, Ardeleanu M. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 2016;387:40-52. [Ref.ID 99988]
12.Tiene citas relacionadas
Tsianakas A, Ständer S. Dupilumab: a milestone in the treatment of atopic dermatitis. Lancet 2016;387:4-5. [Ref.ID 99987]
13. Cita con resumen
Anónimo. Vemurafenib (Zelboraf): risk of potentiation of radiation toxicity. Drug Safety Update 2015;9:2. [Ref.ID 99642]
14. Cita con resumen
Viola E, Pittoni AC, Drahos A, Moretti U, Conforti A. Photosensitivity with angiotensin II receptor blockers: a retrospective study using data from VigiBase. Drug Saf 2015;38:889-94. [Ref.ID 99615]
15. Cita con resumen
Yang C-Y, Chen CH, Deng S-T, Huang C-S, Lin Y-J, Chen Y-J, Wu C-Y, Hung S-L, Chung W-H. Allopurinol use and risk of fatal hypersensitivity reactions: A nationwide population-based study in Taiwan. JAMA Intern Med 2015;175:1550-7. [Ref.ID 99256]
17.Enlace a cita original Cita con resumen
Martín-Merino E, de Abajo FJ, Gil M. Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study. Eur J Clin Pharmacol 2015;71:759-66. [Ref.ID 99180]
18. Cita con resumen
Barnes L, Kaya G, Rollason V. Topical corticosteroid-induced skin atrophy: a comprehensive review. Drug Saf 2015;38:493-509. [Ref.ID 99074]
19. Cita con resumen
Anónimo. Galantamine: atteintes cutanées graves. Prescrire 2015;35:105. [Ref.ID 98914]
20. Cita con resumen
Anónimo. Levure de riz rouge: troubles musculaires et hépatiques. Prescrire 2015;35:18. [Ref.ID 98901]
Seleccionar todas
 
 1 a 20 de 509 siguiente >>